Hide
Brief description of measure
CMS646: Intravesical Bacillus-Calmette-Guerin for non-muscle invasive bladder cancer:
Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging.
Description of issue
The denominator exception language in the header does not clearly describe the logic and timing. The measure developer would like to reduce confusion by implementers and provide additional language.
Goal of review
Obtain clinical feedback
Show
Brief description of measure
CMS646: Intravesical Bacillus-Calmette-Guerin for non-muscle invasive bladder cancer:
Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging.
Description of issue
The denominator exception language in the header does not clearly describe the logic and timing. The measure developer would like to reduce confusion by implementers and provide additional language.
Goal of review
Obtain clinical feedback